The endosomal-lysosomal system in ADC design and cancer therapy

References

• Dumontet C, Reichert JM, Senter PD, et al. Antibody–drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023 Aug;22(8):641–661. doi: 10.1038/s41573-023-00709-2
   PubMed Web of Science ®Google Scholar
• Hoffmann RM, Coumbe BGT, Josephs DH, et al. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology. 2018;7(3):e1395127. doi: 10.1080/2162402X.2017.1395127
   PubMed Web of Science ®Google Scholar
• Qi X, Li Y, Liu W, et al. Research trend of publications concerning antibody-drug conjugate in solid cancer: a bibliometric study. Front Pharmacol. 2022;13:921385. doi: 10.3389/fphar.2022.921385
   PubMed Web of Science ®Google Scholar
• Hammood M, Craig AW, Leyton JV. Impact of endocytosis mechanisms for the receptors targeted by the currently approved antibody-drug conjugates (ADCs)—a necessity for future ADC research and development. Pharmaceuticals (Basel). 2021 Jul 15;14(7):674. doi: 10.3390/ph14070674
   PubMedGoogle Scholar
• Jin Y, Schladetsch MA, Huang X, et al. Stepping forward in antibody-drug conjugate development. Pharmacol Ther. 2022 Jan;229:107917.
   PubMed Web of Science ®Google Scholar
• Leyton JV. Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2. Antibodies (Basel). 2020 Jul 13;9(3):32. doi: 10.3390/antib9030032
   PubMedGoogle Scholar
• Mellman I, Yarden Y. Endocytosis and cancer. Cold Spring Harb Perspect Biol. 2013 Dec 1;5(12):a016949. doi: 10.1101/cshperspect.a016949
   PubMed Web of Science ®Google Scholar
• Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008 Nov;8(11):835–850. doi: 10.1038/nrc2521
   PubMed Web of Science ®Google Scholar
• Banushi B, Joseph SR, Lum B, et al. Endocytosis in cancer and cancer therapy. Nat Rev Cancer. 2023 Jul;23(7):450–473. doi: 10.1038/s41568-023-00574-6
   PubMed Web of Science ®Google Scholar
• Chen YF, Xu YY, Shao ZM, et al. Resistance to antibody-drug conjugates in breast cancer: mechanisms and solutions. Cancer Commun (Lond). 2023 Mar;43(3):297–337. doi: 10.1002/cac2.12387
   PubMed Web of Science ®Google Scholar
• Khoury R, Saleh K, Khalife N, et al. Mechanisms of resistance to antibody-drug conjugates. Int J Mol Sci. 2023 Jun 2;24(11):9674. doi: 10.3390/ijms24119674
   PubMed Web of Science ®Google Scholar
• Wandinger-Ness A, Zerial M. Rab proteins and the compartmentalization of the endosomal system. Cold Spring Harb Perspect Biol. 2014 Oct 23;6(11):a022616. doi: 10.1101/cshperspect.a022616
   PubMed Web of Science ®Google Scholar
• Jin H, Tang Y, Yang L, et al. Rab GTPases: central coordinators of membrane trafficking in cancer. Front Cell Dev Biol. 2021;9:648384. doi: 10.3389/fcell.2021.648384
   PubMed Web of Science ®Google Scholar
• Frittoli E, Palamidessi A, Marighetti P, et al. A RAB5/RAB4 recycling circuitry induces a proteolytic invasive program and promotes tumor dissemination. J Cell Bio. 2014 Jul 21;206(2):307–328. doi: 10.1083/jcb.201403127
   PubMed Web of Science ®Google Scholar
• Engebraaten O, Yau C, Berg K, et al. RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer. Nat Commun. 2021 Nov 5;12(1):6427. doi: 10.1038/s41467-021-26018-z
   PubMed Web of Science ®Google Scholar
• Squires H, Stevenson M, Simpson E, et al. Trastuzumab emtansine for treating HER2-positive, unresectable, locally advanced or metastatic breast cancer after treatment with trastuzumab and a taxane: an evidence review group perspective of a NICE single technology appraisal. Pharmaco Eco. 2016 Jul;34(7):673–680. doi: 10.1007/s40273-016-0386-z
   PubMed Web of Science ®Google Scholar
• Barok M, Puhka M, Vereb G, et al. Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation. BMC Cancer. 2018 May 2;18(1): 504. 10.1186/s12885-018-4418-2
   PubMedGoogle Scholar
• Tkach M, Thery C. Communication by extracellular vesicles: where we are and where we need to go. Cell. 2016 Mar 10;164(6):1226–1232. doi: 10.1016/j.cell.2016.01.043
   PubMed Web of Science ®Google Scholar
• Loganzo F, Tan X, Sung M, et al. Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. Mol Cancer Ther. 2015 Apr;14(4):952–963. doi: 10.1158/1535-7163.MCT-14-0862
   PubMed Web of Science ®Google Scholar
• Grigoriev I, Splinter D, Keijzer N, et al. Rab6 regulates transport and targeting of exocytotic carriers. Dev Cell. 2007 Aug;13(2):305–314. doi: 10.1016/j.devcel.2007.06.010
   PubMed Web of Science ®Google Scholar
• Wei D, Zhan W, Gao Y, et al. RAB31 marks and controls an ESCRT-independent exosome pathway. Cell Res. 2021 Feb;31(2):157–177. doi: 10.1038/s41422-020-00409-1
   PubMed Web of Science ®Google Scholar
• Wang L, Wang Q, Xu P, et al. YES1 amplification confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive cancer. Br J Cancer. 2020 Sep;123(6):1000–1011. doi: 10.1038/s41416-020-0952-1
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang C, Ding J, et al. miR-133a targets YES1 to reduce cisplatin resistance in ovarian cancer by regulating cell autophagy. Cancer Cell Int. 2022 Jan 10;22(1):15. doi: 10.1186/s12935-021-02412-x
   PubMed Web of Science ®Google Scholar
• Ullrich O, Reinsch S, Urbe S, et al. Rab11 regulates recycling through the pericentriolar recycling endosome. J Cell Bio. 1996 Nov;135(4):913–924. doi: 10.1083/jcb.135.4.913
   PubMed Web of Science ®Google Scholar
• Sato I, Obata Y, Kasahara K, et al. Differential trafficking of src, Lyn, Yes and Fyn is specified by the state of palmitoylation in the SH4 domain. J Cell Sci. 2009 Apr 1;122(Pt 7):965–975. doi: 10.1242/jcs.034843
   PubMed Web of Science ®Google Scholar
• Trivedi PC, Bartlett JJ, Pulinilkunnil T. Lysosomal biology and function: modern view of cellular debris bin. Cells. 2020 May 4;9(5):1131. doi: 10.3390/cells9051131
   PubMed Web of Science ®Google Scholar
• Perera RM, Zoncu R. The lysosome as a regulatory hub. Annu Rev Cell Dev Biol. 2016 Oct 6;32(1):223–253. doi: 10.1146/annurev-cellbio-111315-125125
   PubMedGoogle Scholar
• Nadal-Serrano M, Morancho B, Escriva-de-Romani S, et al. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers (Basel). 2020 Mar 13;12(3):670. doi: 10.3390/cancers12030670
   PubMed Web of Science ®Google Scholar
• Rios-Luci C, Garcia-Alonso S, Diaz-Rodriguez E, et al. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res. 2017 Sep 1;77(17):4639–4651. doi: 10.1158/0008-5472.CAN-16-3127
   PubMed Web of Science ®Google Scholar
• Wang H, Wang W, Xu Y, et al. Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells. Cancer Sci. 2017 Jul;108(7):1458–1468. doi: 10.1111/cas.13253
   PubMed Web of Science ®Google Scholar
• Steinman RM, Mellman IS, Muller WA, et al. Endocytosis and the recycling of plasma membrane. J Cell Bio. 1983 Jan;96(1):1–27. doi: 10.1083/jcb.96.1.1
   PubMed Web of Science ®Google Scholar
• Mahmutefendic H, Blagojevic Zagorac G, Macesic S, et al. Chapter 6. Rapid Endosomal Recycling. Peripheral Membrane Proteins: IntechOpen. 2018.
   Google Scholar
• Lynch M, Marinov GK. Membranes, energetics, and evolution across the prokaryote-eukaryote divide. Elife. 2017 Mar 16;6. doi: 10.7554/eLife.20437
   PubMed Web of Science ®Google Scholar
• Erazo-Oliveras A, Fuentes NR, Wright RC, et al. Functional link between plasma membrane spatiotemporal dynamics, cancer biology, and dietary membrane-altering agents. Cancer Metastasis Rev. 2018 Sep;37(2–3):519–544. doi: 10.1007/s10555-018-9733-1
   PubMed Web of Science ®Google Scholar
• Huotari J, Helenius A. Endosome maturation. EMBO J. 2011 Aug 31;30(17):3481–3500. doi: 10.1038/emboj.2011.286
   PubMed Web of Science ®Google Scholar
• Cullen PJ, Steinberg F. To degrade or not to degrade: mechanisms and significance of endocytic recycling. Nat Rev Mol Cell Biol. 2018 Nov;19(11):679–696. doi: 10.1038/s41580-018-0053-7
   PubMed Web of Science ®Google Scholar
• Elkin SR, Bendris N, Reis CR, et al. A systematic analysis reveals heterogeneous changes in the endocytic activities of cancer cells. Cancer Res. 2015 Nov 1;75(21):4640–4650. doi: 10.1158/0008-5472.CAN-15-0939
   PubMed Web of Science ®Google Scholar
• Grant BD, Donaldson JG. Pathways and mechanisms of endocytic recycling. Nat Rev Mol Cell Biol. 2009 Sep;10(9):597–608. doi: 10.1038/nrm2755
   PubMed Web of Science ®Google Scholar
• Ivanova D, Cousin MA. Synaptic vesicle recycling and the endolysosomal system: a reappraisal of form and function. Front Synaptic Neurosci. 2022;14:826098. doi: 10.3389/fnsyn.2022.826098
   PubMed Web of Science ®Google Scholar
• Jonker CTH, Deo C, Zager PJ, et al. Accurate measurement of fast endocytic recycling kinetics in real time. J Cell Sci. 2020 Jan 22;133(2). doi: 10.1242/jcs.231225
   PubMed Web of Science ®Google Scholar
• Mayle KM, Le AM, Kamei DT. The intracellular trafficking pathway of transferrin. Biochim Biophys Acta. 2012 Mar;1820(3):264–281. doi: 10.1016/j.bbagen.2011.09.009
   PubMed Web of Science ®Google Scholar
• Candelaria PV, Leoh LS, Penichet ML, et al. Antibodies targeting the transferrin receptor 1 (TfR1) as direct anti-cancer agents. Front Immunol. 2021;12:607692. doi: 10.3389/fimmu.2021.607692
   PubMed Web of Science ®Google Scholar
• Dautry-Varsat A, Ciechanover A, Lodish HF. pH and the recycling of transferrin during receptor-mediated endocytosis. Proc Natl Acad Sci U S A. 1983 Apr;80(8):2258–2262. doi: 10.1073/pnas.80.8.2258
   PubMed Web of Science ®Google Scholar
• Kleven MD, Jue S, Enns CA. Transferrin receptors TfR1 and TfR2 bind transferrin through differing mechanisms. Biochemistry. 2018 Mar 6;57(9):1552–1559. doi: 10.1021/acs.biochem.8b00006
   PubMed Web of Science ®Google Scholar
• Hopkins CR. The appearance and internalization of transferrin receptors at the margins of spreading human tumor cells. Cell. 1985 Jan;40(1):199–208. doi: 10.1016/0092-8674(85)90323-X
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Schwartz AL, Dautry-Varsat A, et al. Kinetics of internalization and recycling of transferrin and the transferrin receptor in a human hepatoma cell line. Effect of lysosomotropic agents. J Biol Chem. 1983 Aug 25;258(16):9681–9689. doi: 10.1016/S0021-9258(17)44551-0
   PubMed Web of Science ®Google Scholar
• Hopkins CR, Trowbridge IS. Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. J Cell Bio. 1983 Aug;97(2):508–521. doi: 10.1083/jcb.97.2.508
   PubMed Web of Science ®Google Scholar
• van der Ende A, du Maine A, Schwartz AL, et al. Modulation of transferrin-receptor activity and recycling after induced differentiation of BeWo choriocarcinoma cells. Biochem J. 1990 Sep 1;270(2):451–457. doi: 10.1042/bj2700451
   PubMed Web of Science ®Google Scholar
• van der Sluijs P, Hull M, Webster P, et al. The small GTP-binding protein rab4 controls an early sorting event on the endocytic pathway. Cell. 1992 Sep 4;70(5):729–740. doi: 10.1016/0092-8674(92)90307-X
   PubMed Web of Science ®Google Scholar
• Lakadamyali M, Rust MJ, Zhuang X. Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell. 2006 Mar 10;124(5):997–1009. doi: 10.1016/j.cell.2005.12.038
   PubMed Web of Science ®Google Scholar
• Ren M, Xu G, Zeng J, et al. Hydrolysis of GTP on rab11 is required for the direct delivery of transferrin from the pericentriolar recycling compartment to the cell surface but not from sorting endosomes. Proc Natl Acad Sci U S A. 1998 May 26;95(11):6187–6192. doi: 10.1073/pnas.95.11.6187
   PubMed Web of Science ®Google Scholar
• Hattula K, Furuhjelm J, Tikkanen J, et al. Characterization of the Rab8-specific membrane traffic route linked to protrusion formation. J Cell Sci. 2006 Dec 1;119(Pt 23):4866–4877. doi: 10.1242/jcs.03275
   PubMed Web of Science ®Google Scholar
• Weissman AM, Klausner RD, Rao K, et al. Exposure of K562 cells to anti-receptor monoclonal antibody OKT9 results in rapid redistribution and enhanced degradation of the transferrin receptor. J Cell Bio. 1986 Mar;102(3):951–958. doi: 10.1083/jcb.102.3.951
   PubMed Web of Science ®Google Scholar
• Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta. 2012 Mar;1820(3):291–317. doi: 10.1016/j.bbagen.2011.07.016
   PubMed Web of Science ®Google Scholar
• Johnson M, El-Khoueiry A, Hafez N, et al. Phase I, first-in-human study of the probody therapeutic CX-2029 in adults with advanced solid tumor malignancies. Clin Cancer Res. 2021 Aug 15;27(16):4521–4530. doi: 10.1158/1078-0432.CCR-21-0194
   PubMed Web of Science ®Google Scholar
• Luria-Perez R, Helguera G, Rodriguez JA. Antibody-mediated targeting of the transferrin receptor in cancer cells. Bol Med Hosp Infant Mex. 2016 Nov;73(6):372–379. doi: 10.1016/j.bmhimx.2016.11.004
   PubMedGoogle Scholar
• Polson AG, Yu SF, Elkins K, et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood. 2007 Jul 15;110(2):616–623. doi: 10.1182/blood-2007-01-066704
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015 Jun;16(6):704–715. doi: 10.1016/S1470-2045(15)70128-2
   PubMed Web of Science ®Google Scholar
• Pinilla-Macua I, Sorkin A. Methods to study endocytic trafficking of the EGF receptor. Methods Cell Biol. 2015;130:347–367.
   PubMed Web of Science ®Google Scholar
• Rosenkranz AA, Slastnikova TA. Epidermal growth factor receptor: key to selective intracellular delivery. Biochemistry (Mosc). 2020 Sep;85(9):967–1092. doi: 10.1134/S0006297920090011
   PubMed Web of Science ®Google Scholar
• Henriksen L, Grandal MV, Knudsen SL, et al. Internalization mechanisms of the epidermal growth factor receptor after activation with different ligands. PLoS One. 2013;8(3):e58148. doi: 10.1371/journal.pone.0058148
   PubMed Web of Science ®Google Scholar
• Ebner R, Derynck R. Epidermal growth factor and transforming growth factor-alpha: differential intracellular routing and processing of ligand-receptor complexes. Cell Regul. 1991 Aug;2(8):599–612. doi: 10.1091/mbc.2.8.599
   PubMedGoogle Scholar
• Clague MJ, Liu H, Urbe S. Governance of endocytic trafficking and signaling by reversible ubiquitylation. Dev Cell. 2012 Sep 11;23(3):457–467. doi: 10.1016/j.devcel.2012.08.011
   PubMed Web of Science ®Google Scholar
• Chiaruttini N, Roux A. Dynamic and elastic shape transitions in curved ESCRT-III filaments. Curr Opin Cell Biol. 2017 Aug;47:126–135. doi: 10.1016/j.ceb.2017.07.002
   PubMed Web of Science ®Google Scholar
• Francavilla C, Papetti M, Rigbolt KT, et al. Multilayered proteomics reveals molecular switches dictating ligand-dependent EGFR trafficking. Nat Struct Mol Biol. 2016 Jun;23(6):608–618. doi: 10.1038/nsmb.3218
   PubMed Web of Science ®Google Scholar
• Takahashi JI, Nakamura S, Onuma I, et al. Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. Sci Rep. 2022 Jul 7;12(1):11561. doi: 10.1038/s41598-022-15838-8
   PubMed Web of Science ®Google Scholar
• Fan J, Zhuang X, Yang X, et al. A multivalent biparatopic EGFR-targeting nanobody drug conjugate displays potent anticancer activity in solid tumor models. Signal Transduct Target Ther. 2021 Sep 3;6(1):320. doi: 10.1038/s41392-021-00666-5
   PubMed Web of Science ®Google Scholar
• Gandullo-Sanchez L, Pandiella A. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs. Cancer Lett. 2023 Feb 1;554:216024. doi: 10.1016/j.canlet.2022.216024
   PubMed Web of Science ®Google Scholar
• Hu XY, Wang R, Jin J, et al. An EGFR-targeting antibody-drug conjugate LR004-VC-MMAE: potential in esophageal squamous cell carcinoma and other malignancies. Mol Oncol. 2019 Feb;13(2):246–263. doi: 10.1002/1878-0261.12400
   PubMed Web of Science ®Google Scholar
• Perez Verdaguer M, Zhang T, Paulo JA, et al. Mechanism of p38 MAPK–induced EGFR endocytosis and its crosstalk with ligand-induced pathways. J Cell Bio. 2021 Jul 5;220(7). doi: 10.1083/jcb.202102005
   PubMed Web of Science ®Google Scholar
• Tanaka T, Zhou Y, Ozawa T, et al. Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation. J Biol Chem. 2018 Feb 16;293(7):2288–2301. doi: 10.1074/jbc.M117.811299
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang J, Liu C, et al. Neratinib induces ErbB2 ubiquitylation and endocytic degradation via HSP90 dissociation in breast cancer cells. Cancer Lett. 2016 Nov 28;382(2):176–185. doi: 10.1016/j.canlet.2016.08.026
   PubMed Web of Science ®Google Scholar
• Li BT, Michelini F, Misale S, et al. HER2-mediated internalization of cytotoxic agents in ERBB2 amplified or mutant lung cancers. Cancer Discov. 2020 May;10(5):674–687. doi: 10.1158/2159-8290.CD-20-0215
   PubMed Web of Science ®Google Scholar
• McDonough H, Patterson C. CHIP: a link between the chaperone and proteasome systems. Cell Stress Chaperones. 2003;8(4):303–308. Winter. doi: 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2
   PubMed Web of Science ®Google Scholar
• Citri A, Alroy I, Lavi S, et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 2002 May 15;21(10):2407–2417. doi: 10.1093/emboj/21.10.2407
   PubMed Web of Science ®Google Scholar
• Mukohara T, Hosono A, Mimaki S, et al. Effects of ado-trastuzumab emtansine and Fam-trastuzumab Deruxtecan on metastatic breast cancer Harboring HER2 amplification and the L755S mutation. Oncology. 2021 Aug;26(8):635–639. doi: 10.1002/onco.13715
   Google Scholar